Various plasminogen activators have been routinely used for the treatment of thrombotic
diseases. However, these agents possess various problems eg short half life and other …

Thrombotic occlusion of the coronary artery, which triggers acute myocardial infarction, is
one of the major causes of death in the USA. Currently, arterial occlusions are treated with …

Thrombus formed in blood vessel is a progressive process, which would lead to life-
threatening thrombotic diseases such as ischemic stroke. Unlike other diseases, the …

Fibrinolytic drugs have been successfully used to manage acute thrombotic and
thromboembolic conditions. However, their narrow administration time window, rapid …

Due to the high morbidity and mortality of cardiovascular diseases, there is an urgent need
for research on antithrombotic strategies. In view of the short half-life, insufficient drug …

Several plasminogen activators (PAs) have been found effective in treating different
thromboembolic diseases. However, administration of conventional thrombolytic therapy is …

In thrombolytic therapy, plasminogen activators (PAs) are still the only group of drug
approved to induce thrombolysis, and therefore, critical for treatment of arterial …

Targeted drug delivery for maintaining blood fluidity can reduce the risks associated with
systemic anticoagulants that can lead to off‐target bleeding. Recently, there has been much …

It remains a major challenge to develop a selective and effective fibrinolytic system for
thrombolysis with minimal undesirable side effects. Herein, we report a multifunctional …

The currently used drug carriers for vascular drug delivery are reviewed. The human
vascular system possesses unique physiological features that can be exploited for …